SCHEMBL17554144

SCHEMBL17554144

COc1ccc(C(=O)Nc2cc(OC)c(OC)cc2C(=O)NCCCN2CCOCC2)cc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.68
CYP2D6 P10635 2/20 0.68
CYP2C9 P11712 2/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
CYP1A2 P05177 1/20 0.68
CYP3A4 P08684 1/20 0.68
CYP2C19 P33261 1/20 0.68
LMNA P02545 2/20 0.68
GAA P10253 3/20 0.67
BCL3 P20749 1/20 0.67
POLB P06746 2/20 0.59
MAPT P10636 1/20 0.57
ALOX15 P16050 1/20 0.57
HSD17B10 Q99714 1/20 0.57
HPGD P15428 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
KDM4E B2RXH2 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17554065 0.87 ALDH1A1 (0.89) ALDH1A1CYP2D6CYP2C9MEN1KMT2A
SCHEMBL30560552 0.87 ALDH1A1 (0.89) ALDH1A1CYP2D6CYP2C9MEN1KMT2A
SCHEMBL17554029 0.86 LMNA (0.62) ALDH1A1CYP2D6CYP2C9MEN1KMT2A
SCHEMBL17554081 0.85 SMN1; SMN2 (0.67) ALDH1A1CYP2D6CYP2C9LMNAGAA
SCHEMBL30560579 0.85 SMN1; SMN2 (0.67) ALDH1A1CYP2D6CYP2C9LMNAGAA
SCHEMBL10379079 0.85 CYP2C9 (0.73) ALDH1A1CYP2D6CYP2C9CYP2C19GAA
SCHEMBL17554101 0.84 ALDH1A1 (0.81) ALDH1A1CYP2D6CYP2C9MEN1KMT2A
SCHEMBL17554013 0.84 ALDH1A1 (0.62) ALDH1A1CYP2D6CYP2C9MEN1KMT2A
SCHEMBL30560626 0.83 BCL3 (0.74) ALDH1A1CYP2D6CYP2C9KMT2ALMNA
SCHEMBL17554039 0.83 BCL3 (0.74) ALDH1A1CYP2D6CYP2C9KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3628374-B1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-08-30 EP disclosed
EP-3628374-B1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-08-30 EP disclosed
EP-3628374-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2020-04-01 EP disclosed
EP-3628374-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2020-04-01 EP disclosed
US-20190248756-A1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2019-08-15 US disclosed
US-20190248756-A1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2019-08-15 US disclosed
US-10273218-B2 BCL-3 inhibitors UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2019-04-30 US disclosed
US-10273218-B2 BCL-3 inhibitors UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2019-04-30 US disclosed
US-20170267653-A1 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2017-09-21 US disclosed
US-20170267653-A1 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2017-09-21 US disclosed
EP-3174602-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2017-06-07 EP disclosed
WO-2016016728-A2 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248756-A1 BCL-3 INHIBITORS BCL3, BCL2, BCL2L13 ALDH1A1 2635/4885CYP2D6 773/4885CYP2C9 898/4885
US-10273218-B2 BCL-3 inhibitors BCL3, BCL2, BCL2L13 ALDH1A1 2830/4885CYP2D6 669/4885CYP2C9 1015/4885
US-20170267653-A1 BCL-3 INHIBITORS BCL3, BCL2, BCL2L13 ALDH1A1 2830/4885CYP2D6 669/4885CYP2C9 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.